Jason Broderick

Isatuximab Approved in Europe for Relapsed/Refractory Myeloma onclive.com/web-exclusives… #mmsm

Olaparib Approaches EU Approval for Frontline Maintenance in Pancreatic Cancer onclive.com/web-exclusives…

Palbociclib Falls Short in Phase 3 Early Breast Cancer Trial onclive.com/web-exclusives… #bcsm

EU Panel Backs Entrectinib for NTRK + Tumors and ROS1 + NSCLC onclive.com/web-exclusives… #lcsm

Alpelisib Nears EU Approval for PIK3CA+ Breast Cancer onclive.com/web-exclusives… #bcsm

FDA Approves Ramucirumab Plus Erlotinib for Frontline EGFR + NSCLC onclive.com/web-exclusives… #ASCO20 #lcsm

FDA Approves Atezolizumab Plus Bevacizumab for Frontline Liver Cancer onclive.com/web-exclusives… #ASCO20

FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC onclive.com/web-exclusives… via @onclive

Alpelisib Impresses in PI3KCA + Breast Cancer After Progression on CDK Inhibition onclive.com/conference-cov… #bcsm #ASCO20

NCCN Adds Rucaparib to Prostate Cancer Guidelines onclive.com/web-exclusives… #pcsm

FDA Grants Onvansertib Fast Track Designation in KRAS + mCRC onclive.com/web-exclusives…

FDA Waives ODAC Review of Margetuximab in HER2+ Breast Cancer onclive.com/web-exclusives… #bcsm

IASLC Survey Illustrates Current Barriers to Molecular Testing in Lung Cancer onclive.com/web-exclusives… #lcsm

Belumosudil Impresses in cGVHD, FDA Submission Started onclive.com/web-exclusives…

Rucaparib Prostate Cancer Approval Sets Stage for Further Research onclive.com/web-exclusives… #pcsm

Immunotherapy Revolutionizes Melanoma Treatment Paradigm onclive.com/web-exclusives… #melsm @YaleCancer @SmilowCancer

Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma onclive.com/web-exclusives… #mmsm

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC onclive.com/web-exclusives… #pcsm

Dr. Agarwal on the FDA Approval of Olaparib in HRR -Mutant mCRPC onclive.com/onclive-tv/dr-… #pcsm

FDA Approves Olaparib for HRR-Mutant mCRPC onclive.com/web-exclusives… #pcsm